Comparative effectiveness of dual-action versus single-action antidepressants for the treatment of depression in people living with HIV/AIDS by Mills, Jon C. et al.
Comparative Effectiveness of Dual-Action versus Single-Action Antidepressants for the 
Treatment of Depression in People Living with HIV/AIDS 
Jon C Mills, PhD, MBA11, Jeffrey S Harman, PhD2, Robert L Cook, MD, MPH3, 
Nicole M Marlow, PhD, MSPH4, Christopher A Harle, PhD5, R. Paul Duncan, PhD4, 
Angela M Bengtson, PhD1, Brian W Pence, PhD, MPH1 
1University of North Carolina, Chapel Hill, Department of Epidemiology 
2Florida State University, Department of Behavioral Sciences and Social Medicine 
3University of Florida, Department of Epidemiology and Medicine 
4University of Florida, Department of Health Services Research, Management and 
Policy 












Depression is the most common psychiatric comorbidity among people living with 
HIV/AIDS (PLWHA). Little is known about the comparative effectiveness between 
different types of antidepressants used to treat depression in this population. We 
compared the effectiveness of dual-action and single-action antidepressants in PLWHA 
for achieving remission from depression. 
Methods: 
We used data from the Centers for AIDS Research Network of Integrated Clinic 
Systems to identify 1,175 new user dual-action or single-action antidepressant 
treatment episodes occurring from 2005-2014 for PLWHA diagnosed with depression. 
The primary outcome was remission from depression defined as a Patient Health 
1
 University of North Carolina, Chapel Hill, Gillings School of Public Health, Department of Epidemiology, 
McGavran-Greenberg 2103B, Chapel Hill, NC 27599. Phone: 919-966-7410 
_________________________________________________________________________________
 
This is the author's manuscript of the article published in final edited form as: 
Mills, J. C., Harman, J. S., Cook, R. L., Marlow, N. M., Harle, C. A., Duncan, R. P., … Pence, B. W. (2017). Comparative 
Effectiveness of Dual-Action versus Single-Action Antidepressants for the Treatment of Depression in People Living 
with HIV/AIDS. Journal of Affective Disorders. https://doi.org/10.1016/j.jad.2017.03.042
 2 
Questionnaire-9 (PHQ-9) score <5. Mean difference in PHQ-9 depressive symptom 
severity was a secondary outcome. The main approach was an intent-to-treat (ITT) 
evaluation complemented with a per protocol (PP) sensitivity analysis. Generalized 
linear models were fitted to estimate treatment effects. 
Results:  
In ITT analysis, 32% of the episodes ended in remission for both dual-action and single-
action antidepressants. The odds ratio (OR) of remission was 1.02 (95%CI=0.63,1.67). 
In PP analysis, 40% of dual-action episodes ended in remission compared to 32% in 
single-action episodes. Dual-action episodes had 1.33 times the odds of remission 
(95%CI=0.55,3.21), however the result was not statistically significant. Non-significant 
differences were also observed for depressive symptom severity. 
Limitations:  
Missing data was common but was addressed with inverse probability weights.  
Conclusions:  
Results suggest that single-action and dual-action antidepressants are equally effective 
in PLWHA. Remission was uncommon highlighting the need to identify health service 
delivery strategies that aid HIV providers in achieving full remission of their patients’ 
depression. 
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Depression is the most common psychiatric disorder among people living with 
HIV/AIDS (Nanni et al., 2015). People living with HIV/AIDS (PLWHA) are two to four 
times as likely to suffer from depression compared to the general population (Kaaya et 
al., 2013; Nanni et al., 2015; Wendorf and Mosack, 2013). Depression is associated 
with suboptimal antiretroviral treatment (ART) adherence, accelerated HIV disease 
progression, decreased quality of life, increased morbidity and premature mortality 
(Nanni et al., 2015).   
Given the consequences of depression for PLWHA, depression treatment is 
extremely important. One common treatment approach is antidepressant medication.  
Several antidepressants with different pharmacological properties are considered 
appropriate for 1st line treatment in PLWHA. Currently selective-serotonin reuptake 
inhibitors (SSRIs) are the most commonly prescribed class of antidepressants to 
PLWHA (Freudenreich et al., 2010). SSRIs (e.g. citalopram) are considered to be 
single–action antidepressants because they impact only one neurotransmitter known as 
serotonin (Delgado, 2009; Rakesh, 2004).  Dual-action antidepressants are another 
category of medications used as treatment for depression in PLWHA. Dual-action 
antidepressants differ from those with single-action in that they impact two 
neurotransmitters thought to be associated with depression (i.e. serotonin, 
norepinephrine, or dopamine) at the same time (Rakesh, 2004).  Examples of dual-
action antidepressants considered appropriate for PLWHA include serotonin-
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norepinephrine reuptake inhibitors (e.g. venlafaxine), bupropion and mirtazapine 
(Adams et al., 2012).  
Randomized controlled trials have demonstrated that antidepressants have high 
levels of efficacy in PLWHA (Hill and Lee, 2013; Himelhoch and Medoff, 2005; Pence et 
al., 2012).  However, there is limited literature that has compared the effectiveness of 
the different antidepressants currently used to treat PLWHA for depression. In fact we 
found only one study that compared a single-action and dual-action antidepressant 
commonly used today among PLWHA (Patel, 2013). This randomized open label eight-
week trial compared mirtazapine (dual-action) to escitalopram (single-action) in a 
sample of seventy HIV positive patients. While remission and response rates did not 
differ statistically, the median Hamilton Rating Scale for Depression (HAM-D) score at 
eight weeks was significantly lower for mirtazapine (median=4) compared to 
escitalopram (median=12) with a p-value of <0.001.  
 In contrast, substantial effort has been given to comparing effectiveness 
between antidepressants among populations without HIV infection (Bauer et al., 2009; 
Bradley and Lenox-Smith, 2013; Delgado, 2009; Gartlehner et al., 2011; Grunebaum et 
al., 2013; Rakesh, 2004; Richelson, 2013). These studies are based on the hypothesis 
that broader spectrum antidepressants with dual action may be more effective than 
those with single action because depression can arise out of dysfunction along multiple 
neurotransmitters pathways (Delgado, 2009; Rakesh, 2004). While earlier studies 
revealed potential advantages for dual-action antidepressants (Bauer et al., 2009; 
Delgado, 2009; Rakesh, 2004), results from a more recent meta-analysis analysis 
concluded that there were no significant differences according to type of medication 
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(Gartlehner et al., 2011). However, there was a paucity of evidence specific to PLWHA 
contained in the meta-analysis, therefore caution is warranted when generalizing the 
conclusion to those with HIV-infection.  
In fact, more nuanced findings from general population studies suggests that 
further investigation of the comparative effectiveness of dual-vs. single-action 
antidepressants is warranted in PLWHA. First, mirtazapine is known to have a faster 
onset of action compared to single-action SSRIs (Gartlehner et al., 2011). While timely 
alleviation of depressive symptoms is important for all people with depression, it is 
especially salient to PLWHA given the negative HIV/AIDS related health consequences 
associated with this psychiatric condition. Secondly, bupropion has a lower risk of 
sexual side effects compared to single-action SSRIs which may lead to better 
antidepressant treatment adherence (Gartlehner et al., 2011) and therefore better 
response. PLWHA have been shown to be at higher risk of sexual dysfunction, 
independent of antidepressant exposure (Bouhnik et al., 2008), therefore in order to 
avoid additional exascerbation of this problem, bupropion may be more advantageous 
in the context of HIV infection. Finally, in a systematic review conducted in 2013, 
authors found sufficient evidence to conclude that SNRIs may have greater efficacy 
than SSRIs for more severe cases of depression. (Bradley and Lenox-Smith, 2013)  
These findings are relevant to PLWHA given depression in HIV/AIDS is typically chronic 
and often accompanied by additional psychiatric diagnoses (e.g. anxiety, substance use 
disorder), which in turn lends itself to greater severity in depressive symptomology.   
Despite the potential advantages from dual-action antidepressants for PLWHA 
highlighted above, a significant gap remains in research comparing antidepressants in 
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PLWHA. To address this gap, we compared the effectiveness of dual-action and single-
action antidepressants for achieving remission from depression among PLWHA. We 
also assessed comparative effectiveness for depression symptom severity.  Results 
from this study have the potential to generate much needed comparative evidence that 
can reduce uncertainty for a physician when choosing an antidepressant to treat 
depression in PLWHA.  We hypothesized that dual-action antidepressants would be 
more effective than single-action antidepressants for achieving remission and reducing 
depression symptoms.   
2. Methods 
2.1. Data and study population  
This comparative effectiveness study used data from the Center for AIDS 
Research Network of Integrated Clinic Systems (CNICS, 2014a). CNICS  is a network 
of eight clinics located across the United States that collects, standardizes and stores 
point of care electronic data obtained during the delivery of routine HIV primary care. 
CNICS collects patient demographic information, documented diagnoses from medical 
records, medication utilization history (pharmacy fill and medical records), HIV 
biomarker lab results (HIV viral load and CD4 T-cell count) and health care appointment 
history.  As of 2005, CNICS began collecting several self-administered patient-reported 
outcome (PRO) surveys assessing symptom severity (e.g. depression, anxiety), quality 
of life and health related behaviors (e.g. alcohol use). PROs are completed during 
clinical appointments at a CNICS site typically occurring every four to six months. Given 
that the outcome of interest described below is derived from a PRO, our study period 
was 2005-2014. 
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We employed a new-user approach (Ray, 2003) to identify antidepressant 
treatment episodes with a minimum washout period of 90-days; meaning participants 
received no treatment with any antidepressant considered in this analysis during a 
period of at least 90 days prior to the treatment episode initial prescription date (index 
date). Additionally, a treatment episode consisted of a twelve-month follow-up period. 
We limited our analysis to the patient’s first occurring treatment episode with the earliest 
index date, therefore a patient could contribute only one observation. Treatment 
episodes were separated into two comparison groups based on the number of 
neurotransmitters impacted by the antidepressant. Dual-action antidepressants were 
defined as the intervention group and included mirtazapine, bupropion, desvenlafaxine, 
duloxetine or venlafaxine (Delgado, 2009; Rakesh, 2004).  Single-action (SSRIs) 
antidepressants were used as the active comparator group. Single-action 
antidepressants included citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine 
or sertraline (Delgado, 2009; Rakesh, 2004).   
The primary analysis used an intent-to-treat approach, in which participants were 
analyzed according to the initial antidepressant prescribed, regardless of whether the 
participant remained on that antidepressant, discontinued, augmented or switched 
medications during the twelve-month follow-up period. Since discontinuation, switching 
and augmenting can introduce bias to the estimates of treatment effects, we conducted 
a sensitivity analysis limiting the sample to per protocol treatment episodes (Brookhart 
et al., 2013). Per protocol treatment episodes were defined as continuous receipt of the 
original medication without switching or augmenting for the entire twelve-month follow-
up period. 
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At the time of the query for this study, the CNICS cohort included 5,777 
participants that had received any type of antidepressant medication (Figure 1). A total 
of 1,642 participants were excluded due to the following: (1) Antidepressants received 
where not medications under investigation in this study; (2) had a diagnosis of a major 
mental illness other than depression with the potential to impact treatment prognosis 
(e.g. bipolar disorder, psychosis); (3) contained unidentifiable dates in their 
antidepressant treatment history which would preclude the identification of valid 
washout periods. After applying the above exclusion criteria, 4,135 participants 
remained.  Among these participants, we identified 1,579 treatment episodes that began 
after January 1, 2005 with a washout period ≥ 90-days. We excluded an additional 211 
treatment episodes because the participant did not have a recorded diagnosis of 
depression.  A depression diagnosis was identified based on CNICS’s verification 
methods for medical diagnoses described elsewhere (CNICS, 2014b).  Finally, 193 
treatment episodes were removed due to missing a baseline HIV viral load or CD4 T-
cell count lab result. This final exclusion was made because we considered these lab 
results to be potential confounders. The final sample included 1,175 new user intent-to-
treat episodes, of which 347 (30%) were for dual-action antidepressants and 828 (70%) 
were for single-action antidepressants.  Of the 1,175 intent-to-treat episodes, 342 (29%) 
met our definition of a per protocol treatment episode.  The per protocol sample 
included 82 (24%) dual-action and 260 (76%) single-action treatment episodes.   
2.2. Measures 
The primary outcome, remission from depression (yes/no), was measured using 
the Patient Healthcare Questionnaire-9 (PHQ-9), a previously validated instrument for 
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assessing depression severity on a scale from 0-27 (Kroenke et al., 2001).  A score of 
<5 was considered to be remission based on the defined severity levels of the PHQ-9 
(Kroenke et al., 2001). The mean difference in depression symptom severity, a 
secondary outcome, was defined as the difference in the raw PHQ-9 score between 
treatment groups. Only the last observation that occurred during the twelve-month 
follow-up period was used in the analysis in order to allow for the maximum amount of 
therapeutic exposure. 
Several categories of pre-index date covariates were used to help control for any 
baseline differences in the two comparison groups.  Medication utilization data was 
used to identify history of single-action or dual-action antidepressant treatments 
(yes/no) prior to the 90-day minimum washout period. Anxiety, any diagnosed history of 
smoking, alcohol use and drug use were obtained from recorded diagnoses in medical 
records. Additional variables included the most recent HIV viral load and CD4 T-cell 
count and any mental health appointments occurring within six months prior to the index 
date. HIV viral load was dichotomized into a binary variable indicating viral suppression 
(yes/no), defined as less than 200 copies/mL (DHHS, 2014). Other baseline covariates 
included CNICS site, health insurance type, gender, race/ethnicity, age at treatment 
initiation, and receipt of ART on the index date (yes/no).   
Additional variables were identified to aid in the interpretation of our results 
reflecting events during the follow-up period.  These variables included augmentation 
(the addition of a new antidepressant medication during the treatment episode where 
receipt of both medications concurrently lasted more than thirty days); switching (the 
addition of a new antidepressant medication during the treatment episode where receipt 
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of both medications concurrently lasted less than thirty days); treatment exposure days 
(the number of continuous days in the treatment episode that the patient received the 
antidepressant identified as the exposure); and continuous receipt of ART during follow-
up. We also identified if the patient had attended an appointment with a psychiatrist or 
non-prescribing mental health specialist. These variables are reported in the 
Supplemental Online Appendix. 
2.3. Confounding and treatment episodes with missing outcomes 
We used inverse probability of treatment (IPT) weights (Austin and Stuart, 2015) 
to balance comparison groups on baseline (pre-index date) covariates that had the 
potential for confounding. IPT weights were computed with a two-step process.  First we 
used logistic regression to model the predicted probability of receiving the intervention 
(dual-action antidepressants). Second, we took the inverse of the predicted probabilities 
from the logistic regression model to derive the IPT weights. Balance between treatment 
groups on baseline covariates was assessed using standardized differences in mean 
and frequencies (Austin and Stuart, 2015). We considered a standard difference of 
≤0.25 to be indicative of good balance on the covariate (Harder et al., 2010).   
While 1,175 intent-to-treat treatment episodes were identified, only 494 (42%) 
had an observed PHQ-9 during the 12-month follow-up period. If PHQ-9 “missingness” 
is related to the treatment group and the value of the outcome, then estimates limited to 
complete cases (treatment episodes with a PHQ-9 at follow-up) will be biased. We 
chose to address this potential bias by using inverse probability of observation weights 
(Seaman and White, 2013). Inverse probability of observation (IPO) weights were 
calculated with the same process as IPT weights, the only difference being weights 
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were modeled as the predicted probability of having an observed PHQ-9 during the 
follow-up period. 
We then multiplied the IPT and IPO weights to create a unified inverse probability 
of treatment and observation (IPTO) weight (Cole et al., 2010). By applying the IPTO 
weights to our sample, we created a theoretical pseudo-population that approximates 
what we would have observed if: (1) All 1,175 treatment episodes had an observed 
PHQ-9 at follow-up and; 2) treatment selection was independent of the observed 
baseline covariates included in the IPT model.   All weights (IPT, IPO and IPTO) were 
stabilized per Harder et al. (2010) and met distributional recommendations (Harder et al. 
2010).  Details regarding the IPT, IPO and IPTO models are provided in the 
Supplemental Online Appendix.  
2.4. Statistical analysis 
Statistical analyses were conducted using Statistical Analysis Software (SAS®) 
version 9.4 (SAS®, 2012).  We estimated the relative odds of achieving remission with 
SAS® PROC GENMOD, whereby a generalized linear model was fitted with a binomial 
distribution and logit link. Additionally, we fitted a generalized linear model with a normal 
distribution and identity link to estimate the mean difference in depression symptom 
severity.  Robust standard errors were used to account for potential bias in standard 
error estimates that can arise when using inverse probability weighting methods.   
2.5. Ethics Approval 
This study was reviewed and approved by the CNICS Research Review 
Committee on December 12, 2014. The University of Florida Institutional Review Board 
approved this study on February 26, 2015. 
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3. Results 
3.1. Intent-to-treat treatment episode characteristics 
Citalopram (single-action) and bupropion (dual-action) were the most commonly 
prescribed antidepressants (see Supplemental Online Appendix). Approximately 19% of 
all patients had a history of being treated with single-action antidepressants prior to the 
current treatment episode, while 11% had prior exposure to dual-action antidepressants 
(Table 1).  The mean age at the index date was 38 (standard deviation [SD] = 10 years) 
with the majority of subjects being white non-Hispanic males. Most subjects (87%) were 
receiving ART on the index date and based on the last lab result in the washout period, 
the mean CD4 T-cell count was 484 (SD = 281) and 69% of the patients were virally 
suppressed.  About one third of the patients had a diagnosis of anxiety and a 
documented history of drug use.  In the dual-action group, patients were more likely to 
have received dual-action antidepressant therapy prior to the current treatment episode, 
to have seen a psychiatrist during the washout period, to be white non-Hispanic, to be 
virally suppressed during the washout period and to have a history of drug use 
compared to patients in the single-action group. IPTO weighting had little influence on 
our results, and were similar to unweighted analyses.  For simplicity we only report the 
estimates from IPTO models. 
3.2. Intent-to-treat analysis 
 After applying IPT weights, the standardized differences for all baseline 
covariates were below the 0.25 threshold, ranging from 0.002 to 0.066 (Table 1). The 
IPTO weighted frequency of remission (32% vs 32%) and mean depression severity 
(9.2 vs 8.1) at follow-up were not statistically different between dual-action and single-
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action treatment episodes, respectively (Table 1). Results of the IPTO weighted 
generalized linear models for both outcomes were not statistically significant (Table 2). 
The odds ratio for achieving remission was 1.02 (95% CI 0.63-1.67).  The mean 
difference in depression symptom severity between groups was 1.1 units on the PHQ-
9’s 0-27 scale (95% CI -0.4-2.6).  
3.3. Per-protocol sensitivity analysis 
Per protocol baseline covariates and outcome values at follow-up are reported in 
Table 3.  In the IPT weighted sample, all baseline covariates had standardized 
differences less than 0.25.  After applying IPTO weights, the frequency of remission at 
follow-up for dual-action treatment episodes was 40% compared to 32% for single-
action treatment episodes, however the difference was not statistically significant. The 
IPTO weighted mean depression severity was lower, but not statistically different, for 
dual-action treatment episodes compared to single-action treatment episodes (6.9 vs 
8.0). Table 4 contains the results of the IPTO weighted generalized linear models. Dual-
action treatment episodes had 1.33 times the odds of ending in remission compared to 
single-action treatment episodes (OR=1.33, 95% CI 0.55-3.21), but this result was not 
statistically significant. The finding for the mean difference in depression symptom 
severity between treatment groups was also not statistically significant  (β=-0.7, 95% CI 
-3.2-1.7).   
4. Discussion 
 
This is the first comparative effectiveness study we are aware of that compared 
dual-action to single-action antidepressants for the treatment of depression in PLWHA 
using data outside clinically controlled environments. We found no evidence to support 
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our hypothesis that dual-action antidepressants were more effective than single-action 
antidepressants in this population.  This finding was the same in both intent-to-treat and 
per protocol analyses.   
Our data suggest that therapeutic changes may have underestimated the 
effectiveness of dual-action relative to single-action antidepressants in intent-to-treat 
analyses.  Specifically, post-index measures reveal that patients in dual-action 
treatment episodes tended to discontinue earlier and switch or augment more frequently 
(see Supplemental Online Appendix).  More frequent changes could be due to lack of 
treatment response or intolerance of side effect profiles. Unfortunately, we did not have 
measures to indicate what precipitated these changes.  However, comparative 
effectiveness is intended to incorporate factors such as treatment alterations, therefore 
based on our data, overall effectiveness appears comparable between dual-action and 
single-action antidepressants. 
 Our results are consistent in part with the only study in the field of HIV/AIDS that 
we identified which compared antidepressants included in our investigation (Patel, 
2013). Similar to Patel et al. (2013), no differences were observed in remission from 
depression between dual-action and single-action antidepressants. However, contrary 
to our findings, Patel et al. (2013) did detect a difference in depression symptom level at 
follow-up. The discrepancy in findings for depression symptom level could be due to 
differences in the survey instruments used for assessing depression (HAM-D vs PHQ-
9).  Additionally, the differences observed by Patel et al. (2013) occurred at week 8, 
whereas our follow-up observation occurred on average 184 days (26 weeks) from the 
index date. 
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 In terms of research outside the field of HIV/AIDS, our results are in line with the 
findings from an Agency for Healthcare Research and Quality systematic review which 
concluded there were no advantages between different classes of antidepressants 
(Gartlehner et al., 2011).  However, our findings differed with Bradley and Lenox-Smith 
(2013) which concluded that dual-action serotonin-norepinephrine reuptake inhibitors 
(e.g. duloxetine) demonstrated greater efficacy compared to single-action SSRIs in 
more severe cases of depression (Bradley and Lenox-Smith, 2013). Had we limited 
dual-action treatment episodes to include only serotonin-norepinephrine reuptake 
inhibitors, we could make a more definitive comparison with Bradley and Lenox-Smith 
(2013). However, we were unable to identify an adequate number of serotonin-
norepinephrine reuptake inhibitor treatment episodes to define our intervention in this 
manner (see Supplemental Online Appendix for the specific medications identified in 
this study). 
 It is also important to note the low frequency of remission we observed for all 
patients in this study.  Only 32% and 34% in total achieved remission at follow-up in the 
intent-to-treat and per protocol analysis, respectively (See Tables 1 and 3).  Our results 
are similar to prior estimates of remission rates (28%) in real world conditions (Pence et 
al., 2012).  However, 32% is well below commonly observed remission rates in 
randomized controlled trials (median of 72%) (Pence et al., 2012).  The differences in 
outcomes between research and standard practice environments suggests that there is 
potential for improvement when treating depression outside controlled settings.  An 
additional implication is that remission may not always be possible and less aggressive 
treatment goals may be more realistic.  Specifically, patients in our study may have 
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experienced substantial reductions in symptom severity but still not fall below the PHQ-
9 definition of remission.  A mean PHQ-9 score of 8 was observed at follow-up in our 
analysis.  A score of 8 is still indicative of mild depression, however, the patient may 
have experienced a significant improvement in depression severity after initiating 
treatment compared to baseline levels. Yet due to inconsistent availability of a pre-
treatment PHQ-9 measure in our dataset, we were unable to examine change in PHQ-9 
score as an outcome. 
Missing or unavailable data was the most significant limitation we faced. We 
were unable to control for baseline depression severity because, as noted above, so 
few patients had a recorded PHQ-9 within the washout period. Given this data limitation, 
we chose not to require a baseline PHQ-9 as an inclusion criterion.  This decision 
increased the probability of unknown bias in the estimation of treatment effects due to 
potential differences in depression severity at baseline.  One possible reason baseline 
depression severity would differ by treatment group is because several medications 
included in our analysis can be used for conditions other than depression.  Bupropion 
(dual-action) is known to be used for smoking cessation (PDR, 2015b). Likewise, 
paroxetine (single-action) can be used for social anxiety disorder (PDR, 2015a). 
Unfortunately, treatment indication was not available in the data, therefore we cannot be 
certain that depression was the primary concern driving the initiation of antidepressant 
treatment.  However, all included medications have a primary indication for depression 
treatment and are commonly used to treat depression in this population.  Additionally, 
we sought to address this indication bias by limiting the sample to patients with a 
recorded diagnosis of depression in their medical record. Nevertheless, even though 
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CNICS has a rigorous method for verifying diagnosis data (CNICS, 2014b), using such 
data raises the potential for miss-classification bias stemming from coding and reporting 
errors as well as missed diagnoses. 
In addition to unobserved depression severity at baseline, we also encountered a 
significant number (58% of the treatment episodes) of missing PHQ-9s during the 
follow-up period.  Given we could not rule out the possibility that depression severity 
was related to missing a PHQ-9 at follow-up, we chose to employ sophisticated 
statistical methods, specifically IPO weights to address this limitation. While IPO 
weighting would not necessarily eliminate all the bias stemming from missing outcomes, 
it is a stronger approach than a complete case analysis which assumes that the missing 
data introduce no bias. 
Several other important treatment selection factors exist that could have 
confounded our findings. For example, given literature suggests that single-action 
medications are the most commonly prescribed antidepressants for depression in 
PLWHA (Freudenreich et al., 2010), clinicians may be more experienced in managing 
this group of medications. Greater familiarity with these medications could improve the 
effectiveness of single-action antidepressants thereby biasing the results towards the 
null, assuming dual-action antidepressants are indeed more effective.  Physician 
specialty (e.g. psychiatrists) could also influence treatment selection as this factor could 
be indicative of experience with a greater variety of antidepressants. Indeed, we did 
observe that participants initiating dual-action antidepressants were somewhat more 
likely to have seen a psychiatrist during the follow-up period compared to participants in 
single-action treatment episodes (39% vs 31%) (Online Supplemental Appendix). 
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However, appointment data also suggests that approximately 59% of the dual-action 
treatment episodes were administered by a prescribing physician other than a 
psychiatrist. These data indicate that non-specialists (e.g. HIV primary care physicians) 
also possess a level of comfort utilizing a variety of antidepressants including both dual-
action and single-action medications. Ultimately, the potential impact of clinician 
experience and specialty described above is unobserved, therefore we used IPT 
weights to balance treatment groups on an observed appointment with a psychiatrist in 
the washout period. This measure may be a crude indicator of whether or not the 
prescribing physician specialized in the treatment of psychiatric disorders.  However, 
our approach only partially addressed this issue as data was not available that 
confirmed the actual physician prescribing the medication.  
An additional unobserved factor that could have biased our results is the 
selection of one type of antidepressant over another based on potential drug 
interactions between ART and antidepressants. While research indicates the 
pharmacokinetics of citalopram, escitalopram, duloxetine and mirtazapine is not known 
to be significantly altered by ART (Adams et al., 2012; Hill and Lee, 2013), interactions 
have been identified between the remaining antidepressants and certain protease 
inhibitors and non-nucleoside reverse transcriptase inhibitors (Hill and Lee, 2013). 
However, the potential impact of the drug interactions (potentiation or inhibition) varied 
by antidepressant and ART combination across both treatment groups, therefore we 
were unable to assess the effect of this factor in the present study. 
A further limitation arose from the fact we were not able to measure adherence to 
antidepressant treatment.  Overestimation and underestimation is possible with this 
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factor depending on which group had the higher likelihood of non-adherence.  We found 
no literature that specifically addressed differential rates of adherence based on how we 
classified antidepressants.  However, the absence of literature does not indicate there is 
no difference. Therefore, we cannot speak thoroughly to the impact of this unobserved 
factor.  
Finally, we were limited by how we operationalized the intervention.  First we 
were unable to adequately define receipt of non-pharmacological treatment.  The 
approach we took was to create a weight on a variable indicating the presence of an 
appointment with a mental health specialist at the CNICS clinic. However, we do not 
know the type and quality of therapy provided. Moreover, this approach only identifies a 
sub-set of patients receiving non-pharmacological treatment because the cohort can 
seek this type of treatment elsewhere. Secondly, data limitations prevented us from 
determining the consistency of adequate dosing across treatment groups.   
Despite these limitations, this study makes several significant contributions to the 
field of psychiatric HIV/AIDS research.  First, while our data did not support the 
hypotheses for differential effectiveness, the purpose of a comparative effectiveness 
study is to enhance certainty in treatment decisions.  Our study provides evidence that 
suggests differential effectiveness is not a reason to prefer dual-action antidepressants 
over single-action antidepressants, and medication choice can be driven by other 
factors such as patient preference, side effects, costs and provider familiarity. Second, 
this is the first study to address the question of antidepressant comparative 
effectiveness in a sample limited to PLWHA using data collected outside of controlled 
clinical trials. Given our results show achieving remission from depression in real world 
 20 
settings is difficult for PLWHA, this study highlights the importance for continued 
comparative effectiveness research in this field. Third, this study draws attention to the 
data challenges faced when conducting comparative effectiveness research.  Our 
approach to dealing with data limitations should prove useful to other investigators.   
 There are several future research projects that would logically flow from our 
present study.  Given prior literature has identified citalopram as one of the most 
commonly used antidepressants in PLWHA (Freudenreich et al., 2010), future studies 
could compare the effectiveness of individual antidepressants against this medication.  
This would help inform the validity of the current practice. Additionally, future 
investigations are warranted that aim to increase the probability that patients start 
regimens requiring minimal adjustments (switching, augmenting) and achieve remission 
in the shortest time frame.  Such research could circumvent the negative interaction 
between depression and HIV/AIDS. Finally, the low rates of remission observed in this 
study highlight the need for on-going closely managed antidepressant therapy in 
PLWHA.  In light of this fact, research that compares the long-term effectiveness of 
dual-action and single-action antidepressants is necessary to identify potential 
variations in treatment outcomes that may arise over an extended period of time. 
 In conclusion, we observed no difference in effectiveness between dual-action 
and single-action antidepressants for treatment of depression in PLWHA.  This finding 
suggests both single-action and dual-action antidepressants are appropriate choices for 
first line treatment. However, we also found remission rates substantially lower 
compared to results achieved in randomized controlled trials. Therefore, research is 
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needed to identify health service delivery strategies that can aid HIV providers in 
achieving full remission of their patients’ depression. 
 
Footnotes 
1 People living with HIV/AIDS (PLWHA); Intent-to-treat (ITT), Per protocol (PP); Selective-serotonin reuptake 
inhibitors (SSRIs); Antiretroviral treatment (ART); Center for AIDS Research Network of Integrated Clinic Systems 
CNICS; Patient Healthcare Questionnaire-9 (PHQ-9); Inverse probability of treatment (IPT); Inverse probability of 
treatment weights (IPTW); Inverse probability of observation (IPO); Inverse probability of treatment and observation 
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Table 1 Characteristics of intent-to-treat treatment episodes 


























 % % % 
ST
D  % % % 
ST
D 
Outcomes at follow-up      Outcomes at follow-up* 
  Remission: PHQ-9 < 5 32 30 32 
0.04
2  32 32 32 
0.00
1 


















Covariates at baseline      Covariates at baseline** 
 Receipt of prior ADT (single-action) 
€
 19 20 18 
0.07
0  19 19 19 
0.00
2 
 Receipt of prior ADT (dual-action)
€
 11 21 7 
0.44
4  11 11 11 
0.00
2 
 Psychiatrist appt in washout period
₮
 21 28 18 
0.24
3  21 21 21 
0.00
7 
 Mental health specialist appt in 
washout period
₮
 14 15 13 
0.04
1  14 14 14 
0.00
4 
 Demographics          
   Age, mean (SD) 38 (10) 40 (9) 38 (10) 
0.14





   Male 83 87 82 
0.13
0  84 85 83 
0.06
6 
   White 62 69 59 
0.19
8  61 60 62 
0.02
7 
   Black  26 21 29 
0.18
4  27 28 27 
0.02
1 
   Other/unknown  11 10 12 
0.04
6  12 12 12 
0.01
2 
   Hispanic 17 15 19 
0.09






          
   Private 5 3 6 
0.11
5  5 5 5 
0.00
2 
   Public 27 25 29 
0.07
7  27 26 27 
0.02
4 
   Unknown 66 71 64 
0.13
9  66 67 66 
0.02
0 
   Uninsured 1 0 1 
0.05
2  1 1 1 
0.00
6 
 Health status          
   Viral load <200 mL
¥
 69 73 67 
0.12
1  69 68 69 
0.00
6 



















   Alcohol use× 16 18 15 
0.10
5  16 16 16 
0.00
4 
   Drug use× 34 38 32 
0.13
4  33 33 34 
0.02
3 
   Smoker ever× 40 42 39 
0.04
8  40 39 40 
0.00
6 
   Anxiety× 29 29 28 
0.01
9  28 27 28 
0.02
5 
 On ART at index date 87 89 86 
0.08
9  86 86 86 
0.02
8 
 Clinic          
   A 13 15 12 
0.06
7  13 13 13 
0.00
5 
   B 28 28 28 
0.01
3  29 29 28 
0.01
4 
   C 22 16 25 
0.23
3  22 21 22 
0.02
3 
   D 15 17 14 
0.09
6  15 16 15 
0.01
4 
   E 22 25 20 
0.11
2  21 21 21 
0.00
7 
STD: Standardized difference 
ADT: Antidepressant treatment 
APPT: Appointment 
No statistically significant comparisons at p < 0.05 
*Weighted with inverse probability of treatment and observation (IPTO) weights 
**Weighted with inverse probability of treatment (IPT) weights  
€
 ADT received prior to the current treatment episode but the prior period of treatment did not have a 90-day washout period 
₮
Appointments in the washout period but the appointment did not occur more than 6 months prior to the index date if the washout 
period was more than 90 days  
Ω
 Last insurance status reported in the past year from the index date 
¥
 Labs taken closest to the index date but not occurring more than 6 months prior to the index date if the washout period was more 
than 90 days 
×
 Lifetime occurrence 
 
Table 2 IPTO weighted generalized linear models for intent-to-treat analysis 
 
Remission Depression symptom severity 
 Odds ratio 95% C.I. Mean difference (PHQ-9) 95% C.I. 
Dual-action (Ref: Single-action) 1.02 0.63,1.67 1.1 -0.4,2.6 
IPTO – Inverse probability of treatment and observation 
No statistically significant comparisons at p < 0.05 
 
 
Table 3 Characteristics of per protocol treatment episodes 























 % % % STD  % % % STD 
Outcomes at follow-up      Outcomes at follow-up* 
  Remission: PHQ-9 < 5 39 47 37 
0.20
2  34 40 32 
0.16
9 


















Covariates at baseline      Covariates at baseline** 
 Receipt of prior ADT (single-action) 
€
 19 23 18 
0.13
9  18 16 19 
0.06
3 
 Receipt of prior ADT (dual-action)
€
 11 22 7 
0.49
9  10 10 10 
0.01
6 
 Psychiatrist appt in washout period
₮
 15 18 14 
0.11
3  16 16 16 
0.01
1 
 Mental health specialist appt in washout 
period
₮
 18 21 17 
0.11
0  16 15 17 
0.05
9 
 Demographics          
   Age, mean (SD) 39 (9) 41 (9) 39 (9) 
0.23
4  39 (9) 
39 
(9) 39 (9) 
0.03
3 
   Male 82 90 80 
0.27
9  83 89 81 
0.22
8 
   White 63 71 60 
0.22
2  62 63 62 
0.00
4 
   Black  27 18 30 
0.26
4  28 29 28 
0.02
9 
   Other/unknown  10 11 10 
0.03
2  10 8 10 
0.05
1 
   Hispanic 21 22 21 
0.01





          
   Private 6 6 7 
0.01
8  7 7 7 
0.02
2 
   Public 27 29 27 
0.05
2  26 24 27 
0.05
5 
   Unknown 66 65 67 
0.04
0  67 69 66 
0.06
3 
   Uninsured 0 0 0 0  0 0 0 0 
 Health status          
   Viral load <200 mL
¥
 70 74 68 
0.12
9  69 69 70 
0.01
9 



















   Alcohol use× 12 11 13 
0.05
2  14 16 13 
0.09
9 
   Drug use× 31 38 29 
0.20
3  30 29 31 
0.04
7 
   Smoker ever× 33 30 34 
0.07
1  37 43 34 
0.18
2 
   Anxiety× 25 22 26 
0.08
8  25 26 24 
0.02
4 
 On ART at index date 86 88 86 
0.05
9  85 84 86 
0.05
0 
 Clinic          
   A 16 18 15 
0.09
0  15 14 16 
0.03
7 
   B 35 29 37 
0.15




   C 28 29 28 
0.03
5  27 27 27 
0.01
8 
   D 13 13 13 
0.01
0  12 11 13 
0.04
7 
   E 8 10 8 
0.07
5  8 7 8 
0.03
7 
STD: Standardized difference 
ADT: Antidepressant treatment 
APPT: Appointment 
No statistically significant comparisons at p < 0.05 
*Weighted with inverse probability of treatment and observation (IPTO) weights 
**Weighted with inverse probability of treatment (IPT) weights  
€
 ADT received prior to the current treatment episode but the prior period of treatment did not have a 90-day washout period 
₮
Appointments in the washout period but the appointment did not occur more than 6 months prior to the index date if the washout 
period was more than 90 days  
Ω
 Last insurance status reported in the past year from the index date 
¥
 Labs taken closest to the index date but not occurring more than 6 months prior to the index date if the washout period was more 
than 90 days 
×
 Lifetime occurrence 
 
 
Table 4 IPTO weighted generalized linear models for per protocol analysis 
 
Remission Depression symptom severity 
 Odds ratio 95% C.I. Mean difference (PHQ-9) 95% C.I. 
Dual-action (Ref: Single-action) 1.33 0.55,3.21 -0.7 -3.2,1.7 
IPTO – Inverse probability of treatment and observation 





 Dual-action and single-action antidepressants were compared in people with HIV 
 
 Both types of antidepressants are effective for depression in people with HIV 
 
 Both types of antidepressants are suitable 1st line treatments for people with HIV 
 
 Depression remission rates were lower than results observed in controlled trials 
 
 Comparisons of other health services for depression are needed in people with HIV  
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